In addition to controlling hematocrit and improving splenomegaly and symptoms, ruxolitinib provided durable and comprehensive hematological control, according to results of the RESPONSE study.
Investigators compared the efficacy of ruxolitinib with best available therapy in achieving target elevated hematocrit, white blood cell, and platelet levels. Although the study was not powered to assess thromboembolic events, researchers observed the following:
- There were 1.8 thromboembolic events per 100 patient-years of exposure in ruxolitinib-treated patients.
- This rate in those receiving best available therapy was 8.2/100 patient-years of exposure.
Harrison C, Griesshammer M, Miller C, Masszi T, et al. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. [Published online ahead of print May 17, 2017]. Br J Haematol. doi:10.1111/bjh.14764.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al